Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient ID	Diagnosis	Age/sex	Previous therapies	Donor source for TAA-Ts	Dose of each TAA-T infusion	No. of TAA-T infusions	Treatment arm
Patient 1	HL, NS	54/M	Upfront: ABVDX6, XRT, Relapse: R-ICEx4, auto-HSCT, BvX7, Gem-VinoX2, Allo-HSCT	Allo	0.510⁷/m²	1	Active
Patient 2	HL, NS	36/M	Upfront: ABVDX6, XRT, Relapse: ICEX4, Auto-HSCT, Relapse#2 EverolimusX3, BvX3, NivoX11	Auto	0.510⁷/m²	3	Active
Patient 3	HL, NLP	23/M	Upfront: ABVE-PCX4, Relapse: DA-EPOCH-R, R-ICEX4, XRT, Allo-HSCT	Allo	410⁷/m²	1	Adjuvant (TAA-T infused 6 mo after HSCT)
Patient 4	HL, NS	16/F	Upfront: ABVE-PC X 5, Bv-Gem, Ifos-Vino-Bortezomib,Nivo, Nivo+Bv, Auto-HSCT	Auto	0.5e⁶/m²	1	Adjuvant (TAA-T infused 2 mo after HSCT)
Patient 5	HL, gray zone	47/M	Upfront: ABVDX6, IF XRT, for refractory disease: ICE + BvX2, Auto-HSCT, Bv maintenance, XRT + rituximab, Nivolumab	Auto	210⁷/m²	2	Active
Patient 6	HL, NS	36/M	Upfront: ABVDX3, XRT, Relapse: ICEX2, BvX3, NivoX4	Auto	210⁷/m²	2	Active
Patient 7	HL, NS	33/F	Upfront: ABVDX4, relapse: ICEX3, auto-HSCT, BvX2, Lenalidomide, Bv+Benda, PembroX4, anti-CD25 Mab,Vinblastine+Prednisone	Auto	210⁷/m²	2	Active
Patient 8	HL, NS	36/F	Upfront: ABVDX4, ICEX2, Gem+Oxaliplatin, Bv, acalabrutinib+pembro, anti-CD25 Mab, PembroX5	Auto	210⁷/m²	2	Active
Patient 9	HL, NS	39/M	Upfront: ABVDX6, Relapse: Gem-Cisp-DexX3; Bv; ICEX2, auto-HSCT, NivoX28 doses, ESHAPX4	Auto	210⁷/m²	2	Active
Patient 10	HL, NS	31/F	Upfront: ABVDX6, ICEX2, auto-HSCT, BvX3	Auto	210⁷/m²	1	Active

Patient ID	Diagnosis	Age/sex	Previous therapies	Donor source for TAA-Ts	Dose of each TAA-T infusion	No. of TAA-T infusions	Treatment arm
Patient 1	HL, NS	54/M	Upfront: ABVDX6, XRT, Relapse: R-ICEx4, auto-HSCT, BvX7, Gem-VinoX2, Allo-HSCT	Allo	0.510⁷/m²	1	Active
Patient 2	HL, NS	36/M	Upfront: ABVDX6, XRT, Relapse: ICEX4, Auto-HSCT, Relapse#2 EverolimusX3, BvX3, NivoX11	Auto	0.510⁷/m²	3	Active
Patient 3	HL, NLP	23/M	Upfront: ABVE-PCX4, Relapse: DA-EPOCH-R, R-ICEX4, XRT, Allo-HSCT	Allo	410⁷/m²	1	Adjuvant (TAA-T infused 6 mo after HSCT)
Patient 4	HL, NS	16/F	Upfront: ABVE-PC X 5, Bv-Gem, Ifos-Vino-Bortezomib,Nivo, Nivo+Bv, Auto-HSCT	Auto	0.5e⁶/m²	1	Adjuvant (TAA-T infused 2 mo after HSCT)
Patient 5	HL, gray zone	47/M	Upfront: ABVDX6, IF XRT, for refractory disease: ICE + BvX2, Auto-HSCT, Bv maintenance, XRT + rituximab, Nivolumab	Auto	210⁷/m²	2	Active
Patient 6	HL, NS	36/M	Upfront: ABVDX3, XRT, Relapse: ICEX2, BvX3, NivoX4	Auto	210⁷/m²	2	Active
Patient 7	HL, NS	33/F	Upfront: ABVDX4, relapse: ICEX3, auto-HSCT, BvX2, Lenalidomide, Bv+Benda, PembroX4, anti-CD25 Mab,Vinblastine+Prednisone	Auto	210⁷/m²	2	Active
Patient 8	HL, NS	36/F	Upfront: ABVDX4, ICEX2, Gem+Oxaliplatin, Bv, acalabrutinib+pembro, anti-CD25 Mab, PembroX5	Auto	210⁷/m²	2	Active
Patient 9	HL, NS	39/M	Upfront: ABVDX6, Relapse: Gem-Cisp-DexX3; Bv; ICEX2, auto-HSCT, NivoX28 doses, ESHAPX4	Auto	210⁷/m²	2	Active
Patient 10	HL, NS	31/F	Upfront: ABVDX6, ICEX2, auto-HSCT, BvX3	Auto	210⁷/m²	1	Active

Doses: ≥18 years: 240 mg every 2 weeks or 480 mg every 4 weeks; <18 years: 3 mg/kg, max 240 mg every 2 weeks. ABVD, doxorubicin, bleomycin, vincristine, dacarbazine; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; Auto-HSCT, autologous hematopoietic stem cell transplantation; Benda, bendamustine; Bv, brentuximab; CCR, continued complete remission; Cisp, cisplatin; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; Dex, dexamethasone; ESHAP, etoposide, steroids, ara-C, and cisplatin; Gem, gemcitabine; ICE, ifosphamide, carboplatin, etoposide; Ifos, ifosphamide; Mab, monoclonal antibody; Nivo, nivolumab; NLP, modular lymphocyte predominant; NS, nodular sclerosing; PD, progressive disease; Pembro, pembrolizumab; PMR, partial metabolic response; SD, stable disease nivolumab dose; Vino, vinorelbine; XRT, involved field radiation.

View Large

This Feature Is Available To Subscribers Only